Stockscreener 앱 받기
17.99
4.21%
-0.79
전일 마감가:
$18.78
열려 있는:
$19.12
하루 거래량:
1.38M
Relative Volume:
0.89
시가총액:
$2.81B
수익:
$340.81M
순이익/손실:
$-419.65M
주가수익비율:
-6.3123
EPS:
-2.85
순현금흐름:
$-402.10M
1주 성능:
+5.33%
1개월 성능:
+5.70%
6개월 성능:
+20.98%
1년 성능:
-16.98%
1일 변동 폭
$17.90
$19.14
1주일 범위
$16.96
$19.14
52주 변동 폭
$10.57
$24.34
Denali Therapeutics Inc Stock (DNLI) Company Profile
명칭
Denali Therapeutics Inc
전화
(650) 866-8547
주소
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
DNLI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
17.99 | 2.93B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-04-10 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | 재개 | Morgan Stanley | Overweight |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2025-01-07 | 개시 | Robert W. Baird | Outperform |
| 2025-01-03 | 개시 | William Blair | Outperform |
| 2024-12-16 | 업그레이드 | Stifel | Hold → Buy |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-10-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-09-06 | 개시 | B. Riley Securities | Buy |
| 2023-01-30 | 개시 | SVB Securities | Outperform |
| 2022-12-05 | 개시 | Cowen | Outperform |
| 2022-11-02 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-11-02 | 개시 | BofA Securities | Buy |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-12-10 | 재개 | Raymond James | Mkt Perform |
| 2021-09-21 | 개시 | Oppenheimer | Outperform |
| 2021-09-01 | 개시 | SMBC Nikko | Outperform |
| 2021-05-18 | 개시 | UBS | Buy |
| 2021-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-10 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-16 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-08-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-13 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-02-28 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-02-24 | 개시 | Jefferies | Buy |
| 2020-02-19 | 개시 | Stifel | Hold |
| 2020-01-27 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-09-26 | 개시 | Wedbush | Neutral |
| 2019-09-13 | 개시 | Nomura | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-06-26 | 개시 | H.C. Wainwright | Buy |
| 2018-11-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-11-12 | 개시 | Janney | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-01-02 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 개시 | Goldman | Neutral |
| 2018-01-02 | 개시 | JP Morgan | Overweight |
| 2018-01-02 | 개시 | Morgan Stanley | Overweight |
모두보기
Denali Therapeutics Inc 주식(DNLI)의 최신 뉴스
Aug Chart Watch: Whats the outlook for Denali Therapeutics Incs sectorAnalyst Downgrade & Long Hold Capital Preservation Plans - baoquankhu1.vn
Campbell & CO Investment Adviser LLC Purchases 74,066 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Aug Patterns: Can Denali Therapeutics Inc withstand a market correctionMarket Performance Recap & Weekly High Conviction Trade Ideas - baoquankhu1.vn
FOMO Trade: What makes FTRE stock attractive todayInflation Watch & Smart Allocation Stock Reports - baoquankhu1.vn
Denali Therapeutics stock maintains Buy rating at Goldman Sachs on pipeline progress - Investing.com
Earnings Recap: Is BranchOut Food Inc a strong growth stockAnalyst Upgrade & AI Powered Market Trend Analysis - baoquankhu1.vn
Bear Alert: Will Denali Therapeutics Inc benefit from government policy2025 Market Overview & Fast Entry High Yield Stock Tips - baoquankhu1.vn
DNLI: Imminent approval and strong clinical progress drive growth for transferrin receptor-enabled therapies - TradingView — Track All Markets
Denali Therapeutics unveils portfolio goals for 2026, stock up - MSN
Market Outlook: Is Denali Therapeutics Inc a turnaround storyStop Loss & Stock Portfolio Risk Management - baoquankhu1.vn
Denali Therapeutics Inc. (DNLI) Stock Analysis: Exploring An 83% Upside Potential - DirectorsTalk Interviews
Rate Hike: Can Denali Therapeutics Inc scale operations efficientlyQuarterly Investment Review & Stepwise Trade Signal Implementation - baoquankhu1.vn
Have Denali Therapeutics Insiders Been Selling Stock? - simplywall.st
Why (DNLI) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Is Denali Therapeutics Inc. stock a good choice for value investors2025 Technical Patterns & Daily Volume Surge Trade Alerts - Улправда
What insider trading reveals about Denali Therapeutics Inc. stockRecession Risk & AI Powered Market Trend Analysis - Улправда
Investment Recap: Is Denali Therapeutics Inc stock recession proof2025 Top Gainers & Precise Buy Zone Identification - moha.gov.vn
DNLI Stock Price, Forecast & Analysis | DENALI THERAPEUTICS INC (NASDAQ:DNLI) - Chartmill
Why analysts upgrade Denali Therapeutics Inc. stockQuarterly Trade Report & Low Drawdown Momentum Trade Ideas - Улправда
What RSI levels show for Denali Therapeutics Inc. (4DN) stockJuly 2025 Drop Watch & Low Risk Growth Stock Ideas - Улправда
What dividend safety score for Denali Therapeutics Inc. stockJuly 2025 Weekly Recap & Long-Term Safe Return Strategies - Улправда
Ryan Watts Sells 35,198 Shares of Denali Therapeutics (NASDAQ:DNLI) Stock - MarketBeat
Denali Therapeutics CEO Ryan J. Watts Sells Shares - TradingView — Track All Markets
Is Denali Therapeutics Inc. stock recession proofJuly 2025 Final Week & AI Powered Buy and Sell Recommendations - Улправда
Will Denali Therapeutics Inc. stock reach all time highs in 2025Quarterly Market Summary & Long-Term Growth Plans - Улправда
What risks investors should watch in Denali Therapeutics Inc. stockStochastic Oscillator Alerts & Outstanding Profit Investment - Улправда
Denali Therapeutics (NASDAQ:DNLI) Insider Sells $284,097.00 in Stock - MarketBeat
Assessing Denali Therapeutics (DNLI) Valuation After Positive Hunter Syndrome Trial Data And FDA Priority Review - Yahoo Finance
The Bull Case For Denali Therapeutics (DNLI) Could Change Following NEJM Tividenofusp Data Publication And FDA Review - Yahoo Finance
Performance Recap: Will Denali Therapeutics Inc. stock reach all time highs in 20252025 EndofYear Setup & Risk Managed Investment Entry Signals - Bộ Nội Vụ
Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up - sharewise.com
Will Denali Therapeutics Inc. stock see insider buyingMarket Depth Overview & Unlock Patterns Humans Can’t See - Улправда
Denali Therapeutics outlines key milestones for 2026 By Investing.com - Investing.com Nigeria
Denali Therapeutics stock rating initiated at Buy by UBS on Hunter syndrome drug potential - Investing.com South Africa
Can Denali Therapeutics Inc. (4DN) stock sustain institutional flows2026 world cup usa national team round of 32 young talents transition play winner prediction expert opinion - ulpravda.ru
Denali Prepares For Key Clinical And Regulatory Milestones - Nasdaq
Denali Therapeutics announces key anticipated milestones and priorities for 2026 - MarketScreener
Denali Therapeutics outlines key milestones for 2026 - Investing.com
Denali Therapeutics Sets 2026 Priorities Ahead of Tividenofusp Decision - TipRanks
Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome - The Manila Times
Denali Therapeutics Inc Announces Key Milestones and Priorities for 2026 - TradingView — Track All Markets
Hunter syndrome drug nears FDA decision as new brain therapies move ahead - Stock Titan
Denali Therapeutics announces $200M proposed offering of common stock and pre-funded warrants - MSN
DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study - MSN
Denali Therapeutics Earnings Notes - Trefis
Smart Money: Is Denali Therapeutics Inc stock recession proofM&A Rumor & Daily Technical Stock Forecast Reports - moha.gov.vn
Hunter Syndrome Treatment Market is expected to reach US$ - openPR.com
Denali Therapeutics stock rating initiated at Buy by UBS on Hunter syndrome drug potential By Investing.com - Investing.com Nigeria
Denali’s Hunter syndrome therapy shows promise in Phase 1/2 trial - Investing.com Nigeria
Understanding Momentum Shifts in (DNLI) - Stock Traders Daily
Denali Therapeutics stock holds Buy rating at Jefferies on FDA approval confidence - Investing.com Nigeria
Denali Therapeutics Inc (DNLI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Denali Therapeutics Inc 주식 (DNLI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Schuth Alexander O. | COFO and Secretary |
Jan 06 '26 |
Sale |
16.50 |
17,218 |
284,097 |
282,828 |
4.73%
0.92%
자본화:
|
볼륨(24시간):